{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:06:35Z","timestamp":1783955195805,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,13]]},"DOI":"10.7759\/cureus.112586","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:32:36Z","timestamp":1783953156000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report"],"prefix":"10.7759","author":[{"given":"Isabel V","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pimenta de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng XL","year":"2008","unstructured":"Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008, 3:249-77. 10.1146\/annurev.pathmechdis.3.121806.154311","journal-title":"Annu Rev Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully M","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, et al.. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017, 15:312-22. 10.1111\/jth.13571","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi F","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, et al.. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016, 374:511-22. 10.1056\/NEJMoa1505533","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga JA","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010, 115:1500-11. 10.1182\/blood-2009-09-243790","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.07.005","article-title":"Complement activation and regulation in thrombotic microangiopathies","volume":"30(5)","author":"Giordano M","year":"2010","unstructured":"Giordano M, Noris M, Remuzzi G. Complement activation and regulation in thrombotic microangiopathies. Semin Nephrol. 2010, 30(5):479-93. 10.1016\/j.semnephrol.2010.07.005","journal-title":"Semin Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng XL","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, et al.. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020, 18:2486-95. 10.1111\/jth.15006","journal-title":"J Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp053024","article-title":"Thrombotic thrombocytopenic purpura","volume":"354","author":"George JN","year":"2006","unstructured":"George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006, 354:1927-35. 10.1056\/NEJMcp053024","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi PK","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, et al.. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017, 4:157-64. 10.1016\/S2352-3026(17)30026-1","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock GA","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991, 325:393-7. 10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng XL","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, et al.. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020, 18:2496-502. 10.1111\/jth.15010","journal-title":"J Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully M","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019, 380:335-46. 10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood JP","year":"2013","unstructured":"Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013, 11:481-90. 10.1111\/jth.12114","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto M","year":"2023","unstructured":"Matsumoto M, Miyakawa Y, Kokame K, et al.. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023, 118:529-46. 10.1007\/s12185-023-03657-0","journal-title":"Int J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.060","article-title":"Immune thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, therapy and open issues","volume":"16","author":"Trisolini SM","year":"2024","unstructured":"Trisolini SM, Lagan\u00e0 A, Capria S. Immune thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, therapy and open issues. Mediterr J Hematol Infect Dis. 2024, 16:e2024060. 10.4084\/MJHID.2024.060","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284438","article-title":"Treatment of immune-mediated thrombotic thrombocytopenic purpura without plasma exchange","volume":"109","author":"Capecchi M","year":"2024","unstructured":"Capecchi M, Gazzola G, Agosti P, et al.. Treatment of immune-mediated thrombotic thrombocytopenic purpura without plasma exchange. Haematologica. 2024, 109:2019-23. 10.3324\/haematol.2023.284438","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2025.150896","article-title":"ADAMTS13 testing during clinical remission of immune thrombotic thrombocytopenic purpura: a critical review","volume":"39","author":"Robinson DH","year":"2025","unstructured":"Robinson DH, Huang M, Baggio D, et al.. ADAMTS13 testing during clinical remission of immune thrombotic thrombocytopenic purpura: a critical review. Transfus Med Rev. 2025, 39:150896. 10.1016\/j.tmrv.2025.150896","journal-title":"Transfus Med Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484042-severe-immune-mediated-thrombotic-thrombocytopenic-purpura-with-high-titer-adamts13-inhibitors-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:32:37Z","timestamp":1783953157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484042-severe-immune-mediated-thrombotic-thrombocytopenic-purpura-with-high-titer-adamts13-inhibitors-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.112586","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}